Travere Therapeutics, Inc. reported a net loss of $25.5M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a $121.5M net loss. The table below carries 15 fiscal years, from 2012 to 2025, and the quarters Travere Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
TVTX Net Income by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
TVTX Net Income by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Travere Therapeutics, Inc. financials
Frequently Asked Questions
Travere Therapeutics, Inc. reported a net loss of $25.5M in fiscal year 2025.
Travere Therapeutics, Inc. (TVTX) reported a $321.5M net loss in fiscal year 2024 and a $25.5M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Travere Therapeutics, Inc. (TVTX) reported a $121.5M net loss over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Travere Therapeutics, Inc. (TVTX) net income went from -$15K in fiscal year 2012 to -$25.5M in fiscal year 2025.
Travere Therapeutics, Inc. (TVTX) reported -$52.3M in net income in Q3 2026. This represents a decrease of 303.6% from the same quarter a year earlier.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Travere Therapeutics, Inc. (TVTX) reported on that line in every period on record.